key: cord-0993756-98h578vf
authors: Giroir, Brett P.; Collins, Felicia
title: The State of Sickle Cell Disease Care in the United States: How Can Emergency Medicine Contribute?
date: 2020-09-12
journal: Ann Emerg Med
DOI: 10.1016/j.annemergmed.2020.07.029
sha: 1e492ae2b9f758bcc3101450822f04c4183269c7
doc_id: 993756
cord_uid: 98h578vf

nan

Another persistent challenge for patients with SCD is accessing opioids for acute pain management in the midst of the current national opioid crisis. Restrictive opioidprescribing practices, an important tool for reducing population-level risk for opioid misuse, have been associated with unintended consequences for patients with SCD and others who rely on ready access to opioids for appropriate care. To raise awareness of the potential harm caused by blanket prescribing policies, the HHS Pain Management Best Practices Inter-Agency Task Force's final report called for "a balanced, individualized, patientcentered approach" in managing acute and chronic pain and, as an example, outlined 10 SCD-specific recommendations. Similarly, the Centers for Medicare & Medicaid Services proposed in February 2020 that Medicare beneficiaries with SCD be exempt from drug management programs for opioids and other frequently abused drugs, beginning with plan year 2021.

With this supplement, we aim to highlight the critical role of EDs as frontline health care facilities for SCD care and to identify potential areas for improvement that can be achieved through increased collaboration between emergency physicians, hematologists, and SCD patients and families. The 13 articles in this supplement address broad topics relevant to SCD care, including common clinical presentations in ED settings, as well as emerging diagnostic modalities and barriers to care. Four articles discuss the patient and caregiver experience and psychosocial factors, such as patient stigma and implicit bias.

HHS has prioritized SCD because of its importance to many US families, but also as an exemplar to organize and implement quality-of-care initiatives for a multitude of relatively rare diseases. Early in 2018, we established an interagency HHS SCD work group to coordinate activities across existing federal programs, reduce duplication, and develop bold, transformative initiatives. The work group is Volume 76, no. 3s : September 2020

Annals of Emergency Medicine S1 chaired by the Office of Minority Health and currently comprises 60 members from 12 HHS agencies. The overarching goal of the work group is to increase the life expectancy of individuals living with SCD in the United States by 10 years in 10 years (the 10 Â 10 Initiative). President Trump emphasized the importance of SCD by issuing presidential messages in 2018, 2019, and a proclamation in 2020, the first such acknowledgements since 1983.

One new approach to improve patient care is the SCD Training and Mentoring Program (STAMP) for primary care providers using the Project Extension for Community Healthcare Outcomes (Project ECHO) telehealth platform. The target audience for STAMP includes emergency physicians who often serve as de facto primary care providers for patients with SCD. Launched in January 2020, STAMP is a collaboration of the Office of Minority Health and the Health Resources and Services Administration. This 12-part series, taught by hematologists using a case-based approach, covers basic topics of SCD care, such as multimodal pain management approaches, women's health and SCD, and evaluation and management of headache. Participation in STAMP has exceeded expectations, with an average of almost 50 attendees per session, including several emergency physicians. The initial STAMP recruitment strategy focused on national health care associations, including the American College of Emergency Physicians (ACEP), providers from medium-sized cities where needed SCD specialists are lacking, select health care facility types (eg, federally qualified health centers), and SCD advocacy organizations. Through STAMP, a vibrant community of like-minded specialists and primary care/emergency providers is being cultivated, which can potentially seed additional collaborative opportunities to improve SCD care.

In February 2020, the HHS Office of the Chief Technology Officer launched the Healthþ Sickle Cell Disease Accelerator in partnership with our office. Healthþ focuses on specific, high-influence health issues, with the goal of fostering technology solutions and creative problem solving. As an initial step to achieve this goal, the team interviewed more than 25 individuals living with SCD to identify common challenges hindering access to quality care. Two specific topics, ED care and transition from pediatrics to adult care, were developed into journey maps, which are visually appealing narratives combining data, patient quotes and stories, and graphics. The journey maps enable others to understand more fully the patients' perspective as they navigate the health care system. Both journey maps were used to inform the development of a multistakeholder roundtable and to set the stage for a "Healthathon," launched this month, in which application developers, other technology experts, and SCD stakeholders will meet to develop crowd-sourced solutions addressing some of these challenges.

In July 2020, the Office of Minority Health issued a new funding opportunity ($2.5 million annually for up to 3 years) for state Medicaid offices and partners to develop incentive payment models encouraging providers to increase hydroxyurea use for children living with SCD. Hydroxyurea is a low-cost, long-term medication that has been shown to decrease acute pain crises and episodes of acute chest syndrome, thereby decreasing high rates of ED utilization in this population. The requirements for the grant specify that hydroxyurea performance measures and incentive payment systems be addressed for all major provider types who care for children with SCD, including emergency physicians. The Office of Minority Health developed the grant program based on the premise that all health care encounters are opportunities to educate patients and ensure that evidence-based practice guidelines are being followed. As one example involving EDs, Children's National Hospital in Washington, DC, developed the Quick-Start Hydroxyurea Initiation Project, in which patients with sickle cell anemia, a severe and common form of SCD, who were not receiving hydroxyurea were identified by ED record review and referred for an intensive educational session. Two years after the implementation of the project, the proportion of eligible patients receiving hydroxyurea increased from 56% to 80%. 9 We know it is essential for emergency physicians to be part of discussions to explore and help inform the development of novel, value-based payment systems. If the payment models are successful, they can be replicated by other state Medicaid offices not only for hydroxyurea but also for other evidencebased practices, both for children and adults living with SCD.

Hope and optimism for the future of people living with SCD have never been greater than they are now. In September 2018, the National Heart, Lung, and Blood Institute of the National Institutes of Health launched the Cure Sickle Cell Initiative to accelerate development of the most promising genetic therapies for SCD so they can be safely used in clinical research within 5 to 10 years. The Centers for Medicare & Medicaid Services issued an SCD indicator in June 2019 based on Medicare and Medicaid claims data and released 2 reports describing SCD prevalence in both these beneficiary populations. In September 2019, together with our office, the Centers for Disease Control and Prevention expanded the number of states that are collecting comprehensive, population-level data on SCD, adding 7 (Alabama, Indiana, Michigan, Minnesota, North Carolina, Tennessee, and Virginia) to the original 2 (California and Georgia). In November 2019, the Food and Drug Administration approved 2 new SCD drugs with novel mechanisms of action, crizanlizumab (monoclonal P-selectin inhibitor) and voxelotor (hemoglobin oxygen-affinity modulator), doubling the number of available SCD therapies from 2 to 4. In addition, more than 35 other candidate SCD therapies are in various stages of review in the Food and Drug Administration pipeline. Finally, earlier this month, the National Academies of Sciences, Engineering, and Medicine issued the nation's first SCD consensus report, sponsored by the Office of Minority Health, which outlines a detailed strategic plan and blueprint to guide future SCD interventions, programs, and research activities.

As we engage in these exciting new opportunities, it is essential that we continue to heed and listen intently to individuals living with SCD and to their caregivers. In ED settings, such clear and open communication is crucial for establishing trust, the cornerstone of the patient-physician relationship, which not only affects the quality and effectiveness of care but also can counter previous experiences and assumptions.

We ask the emergency medicine community to partner with hematologists, primary care providers, federal agencies, SCD advocacy organizations, and other stakeholders in using a multidisciplinary, team-based approach to identify solutions that are data driven, patient centered, and compassionate. We encourage wide adoption of warm handoffs between emergency physicians and hematologists, improved awareness and implementation of evidence-based treatment guidelines, and comprehensive coordination of care and supportive services in communities. It is our hope that this supplement will lay a solid foundation for increasing awareness, identifying key issues, and developing progressive, sustainable collaborations that will help attain the goal of a longer quality lifespan for people living with SCD. Authorship: All authors attest to meeting the four ICMJE.org authorship criteria: (1) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND (2) Drafting the work or revising it critically for important intellectual content; AND (3) Final approval of the version to be published; AND (4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). Publication of this supplement was supported by the Office of Minority Health of the US Department of Health and Human Services.

Population estimates of sickle cell disease in the US

The number of people with sickle-cell disease in the United States: national and state estimates

Emergency department utilization by Californians with sickle cell disease

Acute care utilization and rehospitalizations for sickle cell disease

Impact of chronic conditions on emergency department visits of children using Medicaid

Reducing health care disparities in sickle cell disease: a review

Barriers to care for persons with sickle cell disease: the case manager's opportunity to improve patient outcomes

Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders

Targeted hydroxyurea education after an emergency department visit increases hydroxyurea use in children with sickle cell anemia